Combined treatment with antiepileptic drugs. Andalusian epilepsy guide 2015;Tratamiento combinado con fármacos antiepilépticos. Guía Andaluza de Epilepsia 2015

Revista de Neurologia

Volumn 60, Issue 8, 2015, Pages 365-379

  Sánchez ÁLvarez, Juan C ^a   Ramos Lizana, Julio ^a   Machado Casas, Irene S ^a   Serrano Castro, Pedro J ^a   Martínez Antón, Jacinto L ^b   Ruiz Giménez, Jesús ^a  

^a HOSPITAL TORRECÁRDENAS   (Spain)

^b HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

Author keywords

Antiepileptic drugs; Association; Clinical practice guidelines; Combination; Combination therapy; Epilepsy; Metaanalysis; Refractory epilepsy; Resistant epilepsy; Systematic review; Treatment

Indexed keywords

ANTICONVULSIVE AGENT;

ARTICLE; DRUG COMBINATION; EPILEPSY; HUMAN; NEUROLOGIST; PRACTICE GUIDELINE; TREATMENT OUTCOME; AGE; CLASSIFICATION; CLINICAL TRIAL (TOPIC); COMBINATION DRUG THERAPY; COMORBIDITY; CONSENSUS DEVELOPMENT; DRUG POTENTIATION; DRUG RESISTANCE; DRUG SUBSTITUTION; EVIDENCE BASED MEDICINE; FEMALE; MEDICAL SOCIETY; META ANALYSIS (TOPIC); PREGNANCY; PREGNANCY COMPLICATIONS; RISK FACTOR; SEX DIFFERENCE; SPAIN;

AGE FACTORS; ANTICONVULSANTS; CLINICAL TRIALS AS TOPIC; COMORBIDITY; DRUG RESISTANCE; DRUG SUBSTITUTION; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; EPILEPSY; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; META-ANALYSIS AS TOPIC; PREGNANCY; PREGNANCY COMPLICATIONS; RISK FACTORS; SEX FACTORS; SOCIETIES, MEDICAL; SPAIN;

EID: 84927724602     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.6008.2014528     Document Type: Article

References (77)

1. Reynolds EH, Shorvon SD. Mono-or polytherapy of epilepsy? Epilepsia 1981; 22: 1-10.
2. Stephen LJ, Brodie MJ. Antiepileptic drug monotherapy versus polytherapy: pursuing seizure freedom and tolerability in adults. Curr Opin Neurol 2012; 25: 164-72.
3. Elaboración de guías de práctica clínica en el Sistema Nacional de Salud. Manual metodológico. URL: http://www.guiasalud.es/emanuales/elaboracion/index-02.html. [21.11.2014].
4. Deckers CL, Hekster YA, Keyser A, Van Lier HJ, Meinardi H, Renier WO. Monotherapy versus polytherapy for epilepsy: a multicenter double-blind randomized study. Epilepsia 2001; 42: 1387-94.
5. Privitera MD, Brodie MJ, Mattson RH, Chadwick DW, Neto W, Wang S; EPMN 105 Study Group. Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy. Acta Neurol Scand 2003; 107: 165-75.
6. Brodie MJ, Perucca E, Ryvlin P, Ben-Menachem E, Meencke HJ; Levetiracetam Monotherapy Study Group. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology 2007; 68: 402-8.
7. Kwan P, Brodie MJ, Kälviäinen R, Yurkewicz L, Weaver J, Knapp LE. Efficacy and safety of pregabalin versus lamotrigine in patients with newly diagnosed partial seizures: a phase 3, double-blind, randomised, parallel-group trial. Lancet Neurol 2011; 10: 881-90.
8. Baulac M, Brodie MJ, Patten A, Segieth J, Giorgi L. Efficacy and tolerability of zonisamide versus controlled-release carbamazepine for newly diagnosed partial epilepsy: a phase 3, randomised, double-blind, non-inferiority trial. Lancet Neurol 2012; 11: 579-88.
9. Elger CE, Schmidt D. Modern management of epilepsy: a practical approach. Epilepsy Behav 2008; 12: 501-39.
10. French JA, Gazzola DM. Antiepileptic drug treatment: new drugs and new strategies. Continuum (Minneap Minn) 2013; 19: 643-55.
11. Glauser TA, Loddenkemper T. Management of childhood epilepsy. Continuum (Minneap Minn) 2013; 19: 656-81.
12. Brodie MJ, Barry SJ, Bamagous GA, Norrie JD, Kwan P. Patterns of treatment response in newly diagnosed epilepsy. Neurology 2012; 78: 1548-54.
13. Schmidt D, Sillanpää M. Evidence-based review on the natural history of the epilepsies. Curr Opin Neurol 2012; 25: 159-63.
14. Millul A, Iudice A, Adami M, Porzio R, Mattana F, Beghi E; THEOREM Study Group. Alternative monotherapy or add-on therapy in patients with epilepsy whose seizures do not respond to the first monotherapy: an Italian multicentre prospective observational study. Epilepsy Behav 2013; 28: 494-500.
15. Semah F, Thomas P, Coulbaut S, Derambure P. Early add-on treatment vs alternative monotherapy in patients with partial epilepsy. Epileptic Disord 2014; 16: 165-74.
16. Canevini MP, De Sarro G, Galimberti CA, Gatti G, Licchetta L, Malerba A, et al; SOPHIE Study Group. Relationship between adverse effects of antiepileptic drugs, number of coprescribed drugs, and drug load in a large cohort of consecutive patients with drug-refractory epilepsy. Epilepsia 2010; 51: 797-804.
17. Brodie MJ, Sills GJ. Combining antiepileptic drugs –rational polytherapy? Seizure 2011; 20: 369-75.
18. Brigo F, Ausserer H, Tezzon F, Nardone R. When one plus one makes three: the quest for rational antiepileptic polytherapy with supraadditive anticonvulsant efficacy. Epilepsy Behav 2013; 27: 439-42.
19. Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, Mathern G, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 2010; 51: 1069-77.
20. Schiller Y, Najjar Y. Quantifying the response to antiepileptic drugs: effect of past treatment history. Neurology 2008; 70: 54-65.
21. Gilioli I, Vignoli A, Visani E, Casazza M, Canafoglia L, Chiesa V, et al. Focal epilepsies in adult patients attending two epilepsy centers: classification of drug-resistance, assessment of risk factors, and usefulness of ‘new’ antiepileptic drugs. Epilepsia 2012; 53: 733-40.
22. Beyenburg S, Stavem K, Schmidt D. Placebo-corrected efficacy of modern nonenzyme-inducing AEDs for refractory focal epilepsy: systematic review and meta-analysis. Epilepsia 2012; 53: 512-20.
23. Beyenburg S, Stavem K, Schmidt D. Placebo-corrected efficacy of modern antiepileptic drugs for refractory epilepsy: systematic review and meta-analysis. Epilepsia 2010; 51: 7-26.
24. Gao L, Xia L, Zhao FL, Li SC. Clinical efficacy and safety of the newer antiepileptic drugs as adjunctive treatment in adults with refractory partial-onset epilepsy: a meta-analysis of randomized placebo-controlled trials. Epilepsy Res 2013; 103: 31-44.
25. Costa J, Fareleira F, Ascenção R, Borges M, Sampaio C, Vaz-Carneiro A. Clinical comparability of the new antiepileptic drugs in refractory partial epilepsy: a systematic review and meta-analysis. Epilepsia 2011; 52: 1280-91.
26. Rheims S, Perucca E, Cucherat M, Ryvlin P. Factors determining response to antiepileptic drugs in randomized controlled trials. A systematic review and meta-analysis. Epilepsia 2011; 52: 219-33.
27. Bergey GK. Evidence-based treatment of idiopathic generalized epilepsies with new antiepileptic drugs. Epilepsia 2005; 46 (Suppl 9): S161-8.
28. Beydoun A, D’Souza J. Treatment of idiopathic generalized epilepsy –a review of the evidence. Expert Opin Pharmacother 2012; 13: 1283-98.
29. Thomas P, Valton L, Genton P. Absence and myoclonic status epilepticus precipitated by antiepileptic drugs in idiopathic generalized epilepsy. Brain 2006; 129: 1281-92.
30. Somerville ER. Some treatments cause seizure aggravation in idiopathic epilepsies (especially absence epilepsy). Epilepsia 2009; 50 (Suppl 8): S31-6.
31. Go CY, Mackay MT, Weiss SK, Stephens D, Adams-Webber T, Ashwal S, et al; Child Neurology Society; American Academy of Neurology. Evidence-based guideline update: medical treatment of infantile spasms. Report of the Guideline Development Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2012; 78: 1974-80.
32. Hancock EC, Osborne JP, Edwards SW. Treatment of infantile spasms. Cochrane Database Syst Rev 2013; 6: CD001770.
33. Riikonen R. Recent advances in the pharmacotherapy of infantile spasms. CNS Drugs 2014; 28: 279-90.
34. Zou LP, Wang X, Dong CH, Chen CH, Zhao W, Zhao RY. Three-week combination treatment with ACTH + magnesium sulfate versus ACTH monotherapy for infantile spasms: a 24-week, randomized, open-label, follow-up study in China. Clin Ther 2010; 32: 692-700.
35. Arzimanoglou A, French J, Blume WT, Cross JH, Ernst JP, Feucht M, et al. Lennox-Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology. Lancet Neurol 2009; 8: 82-93.
36. Hancock EC, Cross JH. Treatment of Lennox-Gastaut syndrome. Cochrane Database Syst Rev 2013; 2: CD003277.
37. Von Stülpnagel C, Coppola G, Striano P, Müller A, Staudt M, Kluger G. First long-term experience with the orphan drug rufinamide in children with myoclonic-astatic epilepsy (Doose syndrome). Eur J Paediatr Neurol 2012; 16: 459-63.
38. Cramer JA, Sapin C, François C. Indirect comparison of clobazam and other therapies for Lennox-Gastaut syndrome. Acta Neurol Scand 2013; 128: 91-9.
39. Mantoan L, Walker M. Treatment options in juvenile myoclonic epilepsy. Curr Treat Options Neurol 2011; 13: 355-70.
40. Rosenfeld WE, Benbadis S, Edrich P, Tassinari CA, Hirsch E. Levetiracetam as add-on therapy for idiopathic generalized epilepsy syndromes with onset during adolescence: analysis of two randomized, double-blind, placebo-controlled studies. Epilepsy Res 2009; 85: 72-80.
41. Kassaï B, Chiron C, Augier S, Cucherat M, Rey E, Gueyffier F, et al. Severe myoclonic epilepsy in infancy: a systematic review and a meta-analysis of individual patient data. Epilepsia 2008; 49: 343-8.
42. Brigo F, Storti M. Antiepileptic drugs for the treatment of severe myoclonic epilepsy in infancy. Cochrane Database Syst Rev 2013; 11: CD010483.
43. Wirrell EC, Laux L, Franz DN, Sullivan J, Saneto RP, Morse RP, et al. Stiripentol in Dravet syndrome: results of a retrospective U.S. study. Epilepsia 2013; 54: 1595-604.
44. Inoue Y, Ohtsuka Y; STP-1 Study Group. Effectiveness of add-on stiripentol to clobazam and valproate in Japanese patients with Dravet syndrome: additional supportive evidence. Epilepsy Res 2014; 108: 725-31.
45. Kossoff EH. Intractable childhood epilepsy: choosing between the treatments. Semin Pediatr Neurol 2011; 18: 145-9.
46. Brodie MJ, Elder AT, Kwan P. Epilepsy in later life. Lancet Neurol 2009; 8: 1019-30.
47. Perucca E, Tomson T. The pharmacological treatment of epilepsy in adults. Lancet Neurol 2011; 10: 446-56.
48. Vajda FJ, O’Brien TJ, Lander CM, Graham J, Eadie MJ. The teratogenicity of the newer antiepileptic drugs –an update. Acta Neurol Scand 2014; 130: 234-8.
49. Ruiz-Giménez J, Sánchez-Álvarez JC, Cañadillas-Hidalgo F, Serrano-Castro PJ; Andalusian Epilepsy Society. Antiepileptic treatment in patients with epilepsy and other comorbidities. Seizure 2010; 19: 375-82.
50. Villanueva V, Sánchez-Álvarez JC, Peña P, Puig JS, Caballero-Martínez F, Gil-Nagel A. Treatment initiation in epilepsy: an expert consensus in Spain. Epilepsy Behav 2010; 19: 332-42.
51. Felbamate linked to aplastic anemia; warning issued on drug’s use. Am J Hosp Pharm 1994; 51: 2324.
52. Krauss GL, Johnson MA, Miller NR. Vigabatrin-associated retinal cone system dysfunction: electroretinogram and ophthalmologic findings. Neurology 1998; 50: 614-8.
53. Koepp MJ, Edwards M, Collins J, Farrel F, Smith S. Status epilepticus and tiagabine therapy revisited. Epilepsia 2005; 46: 1625-32.
54. FDA Public Health Advisory. Seizures in patients without epilepsy being treated with Gabitril (tiagabine), February 18, 2005. URL: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm051764.htm. [21.11.2014].
55. Restrictions for use of Trobalt ® (retigabine) –treatment may lead to pigment changes of ocular tissues, including retina, and skin, lips and/or nails. URL: http://www.cbg-meb.nl/NR/rdonlyres/1A608EE4-579D-4E4F-85EB-250686F8A5CB/0/130704DHPCTrobaltUK.pdf. [21.11.2014].
56. Perucca P, Gilliam FG. Adverse effects of antiepileptic drugs. Lancet Neurol 2012; 11: 792-802.
57. Hermann B, Meador KJ, Gaillard WD, Cramer JA. Cognition across the lifespan: antiepileptic drugs, epilepsy, or both? Epilepsy Behav 2010; 17: 1-5.
58. Cramer JA. Tolerability of antiepileptic drugs: can we determine differences? Epilepsy Behav 2012; 23: 187-92.
59. Faught E. Adherence to antiepilepsy drug therapy. Epilepsy Behav 2012; 25: 297-302.
60. Johannessen Landmark C, Patsalos PN. Methodologies used to identify and characterize interactions among antiepilepticdrugs. Expert Rev Clin Pharmacol 2012; 5: 281-92.
61. Patsalos PN. Drug interactions with the newer antiepileptic drugs (AEDs) –part 1: pharmacokinetic and pharmacodynamic interactions between AEDs. Clin Pharmacokinet 2013; 52: 927-66.
62. Patsalos PN. Drug interactions with the newer antiepileptic drugs (AEDs) –part 2: pharmacokinetic and pharmacodynamic interactions between AEDs and drugs used to treat non-epilepsy disorders. Clin Pharmacokinet 2013; 52: 1045-61.
63. Stafstrom CE. Mechanisms of action of antiepileptic drugs: the search for synergy. Curr Opin Neurol 2010; 23: 157-63.
64. Wu T, Nagaya Y, Hanada T. Pharmacodynamic and pharmacokinetic interactions of perampanel and other antiepileptic drugs in a rat amygdala kindling model. Seizure 2014: 23: 732-9.
65. Stephen LJ, Forsyth M, Kelly K, Brodie MJ. Antiepileptic drug combinations–have newer agents altered clinical outcomes? Epilepsy Res 2012; 98: 194-8.
66. Margolis JM, Chu BC, Wang ZJ, Copher R, Cavazos JE. Effectiveness of antiepileptic drug combination therapy for partial-onset seizures based on mechanisms of action. JAMA Neurol 2014; 71: 985-93.
67. Villanueva V, López FJ, Serratosa JM, González-Giraldez B, Campos D, Molins A, et al. Control of seizures in different stages of partial epilepsy: LACO-EXP, a Spanish retrospective study of lacosamide. Epilepsy Behav 2013; 29: 349-56.
68. Villanueva V, Serratosa JM, Guillamón E, Garcés M, Giráldez BG, Toledo M, et al. Long-term safety and efficacy of eslicarbazepine acetate in patients with focal seizures: results of the 1-year ESLIBASE retrospective study. Epilepsy Res 2014; 108: 1243-52.
69. Cereghino JJ, Brock JT, Van Meter JC, Penry JK, Smith LD, White BG. The efficacy of carbamazepine combinations in epilepsy. Clin Pharmacol Ther 1975; 18: 733-41.
70. Brodie MJ, Yeun AWC; the 105 Study Group. Lamotrigine ubstitution study: evidence for synergism with sodium valproate. Epilepsy Res 1997; 26: 423-32.
71. Moeller JJ, Rahey SR, Sadler RM. Lamotrigine-valproic acid combination therapy for medically refractory epilepsy. Epilepsia 2009; 50: 475-9.
72. Pisani F, Otero G, Russo MF, Di Perri R, Perucca E, Richens A. The efficacy of valproate-lamotrigine comedication in refractory complex partial seizures: evidence for a pharmacodynamic interaction. Epilepsia 1999; 40: 1141-6.
73. Steinhoff BJ, Ben-Menachem E, Ryvlin P, Shorvon S, Kramer L, Satlin A, et al. Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies. Epilepsia 2013; 54: 1481-9.
74. Machado VH, Palmini A, Bastos FA, Rotert R. Long-term control of epileptic drop attacks with the combination of valproate, lamotrigine, and a benzodiazepine: a ‘proof of concept’, open label study. Epilepsia 2011; 52: 1303-10.
75. Perucca E, Kwan P. Overtreatment in epilepsy: how it occurs and how it can be avoided. CNS Drugs 2005; 19: 897-908
76. Steinhoff BJ, Maren Staack A, Wisniewski I. Seizure control with antiepileptic drug therapy in 517 consecutive adult outpatients at the Kork Epilepsy Centre. Epileptic Disord 2012; 14: 379-87.
77. Poolos NP, Warner LN, Humphreys SZ, Williams S. Comparative efficacy of combination drug therapy in refractory epilepsy. Neurology 2012; 78: 62-8.